UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review

BMC cancer, 2019-11, Vol.19 (1), p.1068-17, Article 1068

2019

Volltextzugriff (PDF)

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

BMC cancer, 2022-06, Vol.22 (1), p.654-654, Article 654

2022

Volltextzugriff (PDF)

Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study

BMC cancer, 2024-08, Vol.24 (1), p.1010-12

2024

Volltextzugriff (PDF)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

BMC cancer, 2021-11, Vol.21 (1), p.1215-1215, Article 1215

2021

Volltextzugriff (PDF)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

BMC cancer, 2020-04, Vol.20 (1), p.356-13, Article 356

2020

Volltextzugriff (PDF)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

BMC cancer, 2017-07, Vol.17 (1), p.484-484, Article 484

2017

Volltextzugriff (PDF)

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation

BMC cancer, 2022-12, Vol.22 (1), p.1295-12, Article 1295

2022

Volltextzugriff (PDF)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

BMC cancer, 2018-02, Vol.18 (1), p.135-135, Article 135

2018

Volltextzugriff (PDF)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

BMC cancer, 2018-07, Vol.18 (1), p.768-768, Article 768

2018

Volltextzugriff (PDF)

Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study

BMC cancer, 2022-12, Vol.22 (1), p.1323-10, Article 1323

2022

Volltextzugriff (PDF)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

BMC cancer, 2017-04, Vol.17 (1), p.281-281, Article 281

2017

Volltextzugriff (PDF)

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013

BMC cancer, 2018-03, Vol.18 (1), p.306-306, Article 306

2018

Volltextzugriff (PDF)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

BMC cancer, 2022-03, Vol.22 (1), p.323-323, Article 323

2022

Volltextzugriff (PDF)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2

BMC cancer, 2018-03, Vol.18 (1), p.238-238, Article 238

2018

Volltextzugriff (PDF)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

BMC cancer, 2021-01, Vol.21 (1), p.57-57, Article 57

2021

Volltextzugriff (PDF)

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

BMC cancer, 2017-11, Vol.17 (1), p.711-711, Article 711

2017

Volltextzugriff (PDF)

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

BMC cancer, 2019-04, Vol.19 (1), p.410-4, Article 410

2019

Volltextzugriff (PDF)

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

BMC cancer, 2017-04, Vol.17 (1), p.245-245, Article 245

2017

Volltextzugriff (PDF)

Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA

BMC cancer, 2018-12, Vol.18 (1), p.1236-1236, Article 1236

2018

Volltextzugriff (PDF)

Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

BMC cancer, 2022-03, Vol.22 (1), p.328-328, Article 328

2022

Volltextzugriff (PDF)

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

BMC cancer, 2014-04, Vol.14 (1), p.294-294, Article 294

2014

Volltextzugriff (PDF)

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

BMC cancer, 2019-10, Vol.19 (1), p.968-968, Article 968

2019

Volltextzugriff (PDF)

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

BMC cancer, 2024-01, Vol.24 (1), p.70-70, Article 70

2024

Volltextzugriff (PDF)

NSCLC molecular testing in Central and Eastern European countries

BMC cancer, 2018-03, Vol.18 (1), p.269-269, Article 269

2018

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBmc Cancer

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(207)
Mit Volltextzugriff
(207)

Publikationsform

Artikel
(207)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A

Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib

Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study

Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA

Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation

Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study

NSCLC molecular testing in Central and Eastern European countries

Aktive Filter

Suchergebnisse filtern